Hubert Chen - 04 Aug 2026 Form 3 Insider Report for Attovia Therapeutics, Inc. (ATTO)

Reporting relationship: Chief Medical Officer
Issuer ticker: ATTO
Reported as of: 04 Aug 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 04 Aug 2026, 19:30:09 UTC
Source filing: View source filing
Reporting owner signature: /s/ Steven Chan, Attorney-in-Fact

Key filing fact

Hubert Chen filed Form 3 for Attovia Therapeutics, Inc. (ATTO) on 04 Aug 2026.

Key facts

This page summarizes Hubert Chen's Form 3 filing for Attovia Therapeutics, Inc. (ATTO).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 04 Aug 2026, 19:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002142262 Primary reporting owner

Chen Hubert

Relationship: Chief Medical Officer
Address: C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS
Signature: /s/ Steven Chan, Attorney-in-Fact
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATTO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,960
Date: 04 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATTO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 04 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 115,446
Exercise price: $3.53
Footnotes: F1

ATTO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 04 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 96,878
Exercise price: $3.53
Footnotes: F2

ATTO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 04 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,731
Exercise price: $4.92
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on March 20, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.

Footnote F2

The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 9, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.

Footnote F3

The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.